Trial reportPharmacological research2020
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
Trial report in Pharmacological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 17 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 17 syntheses or guidelines pooled it, 222 citations in OpenAlex.
- Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2023Pooled it
- The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review.Expert review of anti-infective therapy · 2022Pooled it
- Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges.Global health, epidemiology and genomics · 2022Pooled it
- Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis.Critical care medicine · 2021Pooled it
- Remdesivir for the treatment of COVID-19.The Cochrane database of systematic reviews · 2021Pooled it
- A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic.Scientific reports · 2021Pooled it
- Association of acute kidney injury with the severity and mortality of SARS-CoV-2 infection: A meta-analysis.The American journal of emergency medicine · 2021Pooled it
- Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis.European journal of pharmacology · 2021Pooled it
- Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19.BMC nephrology · 2021Pooled it
- A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients.Dermatologic therapy · 2021Pooled it
- Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.Life sciences · 2021Pooled it
- Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review.Frontiers in medicine · 2021Pooled it
- Can we predict the severe course of COVID-19 - a systematic review and meta-analysis of indicators of clinical outcome?PloS one · 2021Pooled it
- Is there any potential management against COVID-19? A systematic review and meta-analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020Pooled it
- Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Incidence and risk factors of kidney impairment on patients with COVID-19: A meta-analysis of 10180 patients.PloS one · 2020Pooled it
- Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2020Pooled it
- Remdesivir in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- NSP7 Molecular Degrader Attenuates Coronaviral Infection Through the β-TrCP1/FBXO5 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Biodegradation of Chloroquine by a Fungus from Amazonian Soil,Journal of fungi (Basel, Switzerland) · 2025Article
61 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 is causing an increasing number of deaths worldwide because no effective treatment is currently available. Remdesivir has shown in vitro activity against coronaviruses and is a possible antiviral treatment for SARS-CoV-2 infection. This prospective (compassionate), open-label study of remdesivir, which was conducted at Luigi Sacco Hospital, Milan, Italy, between February 23 and March 20, 2020, involved patients with SARS-CoV-2 pneumonia aged ≥18 years undergoing mechanical ventilation or with an oxygen saturation level of ≤94 % in air or a National Early Warning Score 2 of ≥4. The primary outcome was the change in clinical status based on a 7-category ordinal scale (1 = not hospitalised, resuming normal daily activities; 7 = deceased). The 35 patients enrolled from February 23 to March 20, 2020, included 18 in intensive care unit (ICU), and 17 in our infectious diseases ward (IDW). The 10-day course of remdesivir was completed by 22 patients (63 %) and discontinued by 13, of whom eight (22.8 %) discontinued because of adverse events. The median follow-up was 39 days (IQR 25-44). At day 28, 14 (82.3 %) patients from IDW were discharged, two were still hospitalized and one died (5.9 %), whereas in ICU 6 (33.3 %) were discharged, 8 (44.4 %) patients died, three (16.7 %) were still mechanically ventilated and one (5.6 %) was improved but still hospitalized. Hypertransaminasemia and acute kidney injury were the most frequent severe adverse events observed (42.8 % and 22.8 % of the cases, respectively). Our data suggest that remdesivir can benefit patients with SARS-CoV-2 pneumonia hospitalised outside ICU where clinical outcome was better and adverse events are less frequently observed. Ongoing randomised controlled trials will clarify its real efficacy and safety, who to treat, and when.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.